source
- FDA CDER chief says expanding generic GLP-1 drugs is top priority to cut American costsMichael Davis, director of the FDA's Center for Drug Evaluation and Research, highlighted that increasing the supply of generic GLP-1 medicines is a key focus for the agency. He noted that broader…
- Adicet Bio reports early CAR-T therapy improves lupus symptoms, plans pivotal trial as shares fallAdicet Bio said its off-the-shelf CAR-T cell therapy showed signs of efficacy in a small early-stage trial involving patients with systemic lupus erythematosus. The study reported measurable impro…